# OnCo record myeloma-transplant-eligible (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/myeloma-transplant-eligible/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "myeloma-transplant-eligible" ;
  schema:name "Newly diagnosed multiple myeloma, transplant-eligible"@en ;
  schema:alternateName "Transplant-eligible myeloma"@en, "TE NDMM"@en, "Newly diagnosed myeloma, fit for autologous transplant"@en ;
  schema:description "Fit patients with newly diagnosed myeloma receive four drugs at once, then their own stem cells are collected, they are given high-dose chemotherapy, the cells are returned and they continue on maintenance. Adding the CD38 antibody daratumumab to the three-drug backbone, tested in PERSEUS and CASSIOPEIA, means most patients now reach a state where no myeloma can be detected."@en ;
  schema:url <https://onco.cc/cancers/myeloma-transplant-eligible/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Multiple_myeloma> ;
  schema:citation <https://en.wikipedia.org/wiki/Multiple_myeloma>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1445> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/> ;
  onco:targets <https://onco.cc/targets/cd38/>, <https://onco.cc/targets/proteasome/>, <https://onco.cc/targets/cereblon/> ;
  onco:terms <https://onco.cc/terms/vrd/>, <https://onco.cc/terms/autologous-transplant/>, <https://onco.cc/terms/mrd-negativity-myeloma/>, <https://onco.cc/terms/high-risk-myeloma/>, <https://onco.cc/terms/r-iss/>, <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/terms/proteasome-inhibitor/>, <https://onco.cc/terms/imid/> ;
  onco:pipeline <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/isatuximab/>, <https://onco.cc/drugs/ciltacabtagene-autoleucel/>, <https://onco.cc/trials/cartitude-5/>, <https://onco.cc/ideas/idea-car-t-replaces-transplant/>, <https://onco.cc/ideas/idea-mrd-guided-stop-myeloma/> ;
  onco:standardOfCare <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/trials/perseus/>, <https://onco.cc/drugs/isatuximab/>, <https://onco.cc/terms/vrd/>, <https://onco.cc/pairings/cd38-plus-triplet/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/terms/autologous-transplant/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/trials/perseus/>, <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/ideas/idea-mrd-guided-stop-myeloma/>, <https://onco.cc/technologies/ngs-mrd-clonoseq/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/terms/mrd-negativity-myeloma/>, <https://onco.cc/technologies/whole-body-mri/>, <https://onco.cc/technologies/pet-ct/> .